Pseudomonas aeruginosa: Drug Resistance and Mechanism

doi:10.11924/j.issn.1000-6850.casb2023-0073

Abstract

Abstract:

In order to provide new treatment methods and strategies for clinical prevention and treatment of Pseudomonas aeruginosa infection, the inherent resistance, acquired resistance and adaptive resistance of Pseudomonas aeruginosa are summarized in this paper. With the mechanisms of different resistance, the characteristics, development trends and treatment methods of Pseudomonas aeruginosa resistance under different situations are also analyzed. This paper points out that Pseudomonas aeruginosa resistance mainly depends on its high level of inherent and acquired resistance, while its adaptive resistance mainly depends on the formation of biofilm mediation and quorum sensing. It is proposed that clinical Pseudomonas aeruginosa resistance is not the result of a single resistance. In all, the most effective treatment strategy in the future is to carry out combination therapy based on traditional treatment and new treatment.

Key words: Pseudomonas aeruginosa, inherent resistance, acquired resistance, adaptive resistance resistance, mechanisms

CHEN Yu, WANG Lin, QIN Shangshang. Pseudomonas aeruginosa: Drug Resistance and Mechanism[J]. Chinese Agricultural Science Bulletin, 2024, 40(12): 80-84.

References 27

[1]	LIAO C B, HUANG X, WANG Q X, et al. Virulence factors of Pseudomonas aeruginosa and antivirulence strategies to combat its drug resistance[J]. Frontiers in cellular and infection icrobioloy, 2022, 12:1-17.
[2]	CLARK S T, CABALLERO J D, CHEANG M, et al. Phenotypic diversity within a Pseudomonas aeruginosa population infecting an adult with cystic fibrosis[J]. Sci. rep., 2015, 5:10932. doi: 10.1038/srep10932
[3]	EL-FOULY M Z, SHARAF A M, SHAHIN A A M, et al. Biosynthesis of pyocyanin pigment by Pseudomonas aeruginosa[J]. Journal of radiation research and applied sciences, 2015, 8:36-48. doi: 10.1016/j.jrras.2014.10.007 URL
[4]	DRENKARD E. Antimicrobial resistance of Pseudomonas aeruginosa biofilms[J]. Microbes and infection, 2003, 5(13):1213-1219. doi: 10.1016/j.micinf.2003.08.009 URL
[5]	MULCAHY L R, BURNS J L, LORY S, et al. Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis[J]. Journal of bacteriology, 2010, 192(23):6191-6199. doi: 10.1128/JB.01651-09 URL
[6]	BEHZADI P, BARÁTH Z, GAJDÁCS M. It’s not easy being green: a narrative review on the microbiology, virulence and therapeutic prospects of multidrug-resistant Pseudomonas aeruginosa[J]. Antibiotics, 2021, 10(1):42. doi: 10.3390/antibiotics10010042 URL
[7]	EDUARDOVICH I M, FURSOVA N K, POTAPOV V D. Pseudomonas aeruginosa efflux pump superfamily (review of literature)[J]. Klinicheskaia laboratornaia diagnostika, 2022, 67(1):53-58.
[8]	LI H, LUO Y F, WILLIAMS B J, et al. Structure and function of OprD protein in Pseudomonas aeruginosa: from antibiotic resistance to novel therapies[J]. International journal of medical microbiology, 2012, 302(2):63-68. doi: 10.1016/j.ijmm.2011.10.001 URL
[9]	BELLIDO F, MARTIN N L, SIEHNEL R J, et al. Reevaluation, using intact cells, of the exclusion limit and role of porin OprF in Pseudomonas aeruginosa outer membrane permeability[J]. Journal of bacteriology, 1992, 174(16):5196-5203. doi: 10.1128/jb.174.16.5196-5203.1992 URL
[10]	MACFARLANE E L, KWASNICKA A, OCHS M M, et al. PhoP-PhoQ homologues in Pseudomonas aeruginosa regulate expression of the outer-membrane protein OprH and polymyxin B resistance[J]. Molecular microbiology, 1999, 34(2):305-316. doi: 10.1046/j.1365-2958.1999.01600.x URL
[11]	SINDELDECKERAB D, STOODLEY P. The many antibiotic resistance and tolerance strategies of Pseudomonas aeruginosa[J]. Biofilm, 2021, 3:100056 doi: 10.1016/j.bioflm.2021.100056 URL
[12]	BERRAZEG M, JEANNOT K, NTSOGO ENGUENE V Y, et al. Mutations in beta-Lactamase AmpC increase resistance of Pseudomonas aeruginosa isolates to antipseudomonal cephalosporins[J]. Antimicrobial agents and chemotherapy, 2015, 59(10):6248-6255. doi: 10.1128/AAC.00825-15 URL
[13]	POIREL L, DE LA ROSA, JMO NORDMANN P. Acquisition of extended-spectrum beta-lactamase GES-6 leading to resistance to ceftolozane-tazobactam combination in Pseudomonas aeruginosa[J]. Antimicrobial agents and chemotherapy, 2019, 63(1):e01809-18.
[14]	SID AHMED M A, KHAN F A, HADI H A, et al. Association of blaVIM-2, blaPDC-35, blaOXA-10, blaOXA-488 and blaVEB-9 β-lactamase genes with resistance to ceftazidime-avibactam and ceftolozane-tazobactam in multidrug-resistant Pseudomonas aeruginosa[J]. Antibiotics, 2022, 11(2):130. doi: 10.3390/antibiotics11020130 URL
[15]	SECKO D. New mechanisms of antibiotic resistance[J]. Canadian medical association journal, 2006, 174(9):1249-1249. doi: 10.1503/cmaj.060098 URL
[16]	FERNANDEZ L, HANCOCK R E. Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance[J]. Clinical microbiology reviews, 2012, 25(4):661-681. doi: 10.1128/CMR.00043-12 pmid: 23034325
[17]	FANG Z L, ZHANG L Y, HUANG Y M, et al. OprD mutations and inactivation in imipenem-resistant Pseudomonas aeruginosa isolates from China[J]. Infection genetics and evolution, 2014, 21:124-128. doi: 10.1016/j.meegid.2013.10.027 URL
[18]	WOLTER D J, HANSON N D, LISTER P D. Insertional inactivation of oprD in clinical isolates of Pseudomonas aeruginosa leading to carbapenem resistance[J]. Fems microbiology letters, 2004, 236(1):137-143. doi: 10.1111/fml.2004.236.issue-1 URL
[19]	HALL R M, COLLIS C M. Mobile gene cassettes and integrons: capture and spread of genes by site-specific recombination[J]. Molecular microbiology, 1995, 15(4):593-600. pmid: 7783631
[20]	CHEN J, SU Z, LIU Y, et al. Identification and characterization of class 1 integrons among Pseudomonas aeruginosa isolates from patients in Zhenjiang, China[J]. International journal of infectious diseases, 2009, 13(6):717-721. doi: 10.1016/j.ijid.2008.11.014 URL
[21]	KHOSRAVI A D, MOTAHAR M, ABBASI MONTAZERI E. The frequency of class1 and 2 integrons in Pseudomonas aeruginosa strains isolated from burn patients in a burn center of Ahvaz, Iran[J]. Plos one, 2017, 12(8):e0183061.
[22]	SPERO M A, JEFF J, BRETT L, et al. Mechanisms of chlorate toxicity and resistance in Pseudomonas aeruginosa[J]. Molecular microbiology, 2022, 118(4):321-335. doi: 10.1111/mmi.v118.4 URL
[23]	ODUMOSU B T, ADENIYI B A, CHANDRA R. Analysis of integrons and associated gene cassettes in clinical isolates of multidrug resistant Pseudomonas aeruginosa from Southwest Nigeria[J]. Annals of clinical microbiology and antimicrobials, 2013, 12(5):29-35. doi: 10.1186/1476-0711-12-29 URL
[24]	YANG Q, LI Y, FANG L, et al. A novel KPC-113 variant conferring carbapenem and ceftazidime-avibactam resistance in a multidrug-resistant Pseudomonas aeruginosa isolate[J]. Clinical microbiology and infection, 2022, 29(3):387.
[25]	YAEGER L N, COLES V E, CHAN D C, et al. How to kill Pseudomonas-emerging therapies for a challenging pathogen[J]. Ann. New York acad. sci, 2021, 1496(1):59-81. doi: 10.1111/nyas.v1496.1 URL
[26]	THI M T T, WIBOWO D, REHM B H. Pseudomonas Aeruginosa biofilms[J]. Int. j. mol. sci., 2020, 21(22):8671. doi: 10.3390/ijms21228671 URL
[27]	ABDULHAQ N, NAWAZ Z, ZAHOOR M A S, et al. Association of biofilm formation with multi drug resistance in clinical isolates of Pseudomonas aeruginosa[J]. Excli journal, 2020, 19:201-208.